摘要
目的研究消化道肿瘤患者应用替吉奥为基础化疗的效果及安全性。方法选取2011年12月—2016年12月收治的92例消化道肿瘤患者为研究对象,按随机数表法分为研究组与对照组,各46例。对照组接受以氟尿嘧啶为基础的常规化疗,研究组接受以替吉奥为基础的联合药物化疗,比较两组临床症状改善情况、生活质量、不良症状发生情况及临床疗效。结果治疗后,研究组临床症状改善评分、生活质量评分均高于对照组,差异有统计学意义(P<0.05);恶心呕吐、血小板减少、厌食及腹泻不良症状发生率低于对照组,差异具有统计学意义(P<0.05);治疗有效率与肿瘤控制率均高于对照组,差异具有统计学意义(P<0.05)。结论消化道肿瘤患者接受以替吉奥为基础的药物化疗能够有效降低不良症状的发生,改善临床症状,提高治疗有效率与肿瘤控制率,有助于生活质量的改善。
Objective To study the efficacy and safety of tegafur based chemotherapy in gastrointestinal cancer. Methods From December 2011 to December 2016, 92 gastrointestinal cancer patients were selected as the research object, they were randomly divided into study group and control group, 46 cases in each group. The control group received conventional chemotherapy based on fluorouracil, the study group received tegafur based chemotherapy, the improvement of clinical symptoms, quality of life, incidence of adverse symptoms and clinical efficacy were compared between the two groups. Results After treatment, the clinical symptom improvement and score of quality of life in the study group were higher than those of the control group, the difference was statistically significant（P〈0.05）. The incidence of nausea, vomiting, thrombocytopenia, anorexia and diarrhea in the study group was lower than that of the control group,the difference was statistically significant（P〈0.05）. The treatment efficiency and tumor control rate in the study group were higher than those in the control group, the difference was statistically significant（P〈0.05）. Conclusion Gastrointestinal cancer patients treated with tegafur based chemotherapy can effectively reduce the occurrence of adverse symptoms, improve clinical symptoms, improve the treatment effective rate and tumor control rate, and it is help to improve the quality of life.
出处
《中国继续医学教育》
2017年第28期96-98,共3页
China Continuing Medical Education
关键词
替吉奥
消化道肿瘤
安全性
肿瘤控制率
tegafur
gastrointestinal cancer
safety
tumor control rate
